1800 244 735

Huntington's Disease Therapeutics Conference 2014: day 2

HDBuzz reports from the second day of science at the Huntington’s disease therapeutics conference in Palm Springs.

Morning session: Cells, Circuits and Systems

09:06 – The second day of the annual HD therapeutics conference starts with a series of talks on “Cells, circuits and systems”

But first… watch Olympian & world champion rower Sarah Winckless address the Huntington’s Disease Therapeutics Conference

09:09 – The scientists speaking this morning are interested in communication breakdown in the HD brain and how to fix it

09:14 – Mike Levine, ULCA, explains how the “striatum” is wired together. This is the most vulnerable part of the brain in HD patients

09:18 – The brain is complicated! In HD, degenerating tissues are composed of a wide range of cell types, wired together in complex circuits

09:21 – Bal Khakh, UCLA, studies a star-shaped type of cell called an “astrocyte”. The brain is stuffed with these non-neuronal cells

09:22 – In mice, if we put the mutant HD gene in only astrocytes, the brain gets sick. This got Bal interested in astrocytes in HD patients

09:26 – Though astrocytes don’t fire electrical signals like brain cells called neurons, they have really important functions

09:40 – Could changes in astrocytes in the HD brain contribute to dysfunction in other brain cells? Bal is using HD mice to try to find out

09:43 – In HD mice, fixing astrocyte problems leads to improvement in symptoms

09:51 – Lynn Raymond, UBC, studies changes in a specific “synapse” in the HD brain. Synapses are connections between “neurons” in the brain

09:55 – Raymond measures electrical and chemical activity in these synapses in healthy mice and those with the HD mutation

10:00 – Raymond grows neurons from the cortex (surface of the brain) and striatum (deeper part) together to study how they interact

10:08 – Lynne Raymond addressing the conference on the function of synapses http://t.co/RTyfwMzjZk

10:09 – Raymond has found that there are electrical differences in the behavior of the striatal neurons but it’s not clear why

10:10 – Raymond’s aim is to use the cortex-striatum neuron mixture, called co-culture, to test drugs for HD

10:28 – Next up, Mark Bevan of Northwestern University. Bevan studies the electrical activity in ‘brain slices’ from HD mice.

10:33 – Bevan has found abnormally low activity in a part of the striatum called the subthalamic nucleus in HD mice

10:33 – An electrical switch called the NMDA receptor seems to be responsible for this abnormality.

10:40 – Bevan is trying to figure out why this abnormal activity occurs. Work like this is essential to understanding how to fix human brains

11:17 – Anton Reiner, UT, has a long standing interest in mapping patterns of cell loss in HD patient brains. Which cells are first to go?

11:22 – Understanding which brain cell type is most vulnerable in HD might help us understand why some cells die and others don’t

11:24 – While Reiner has studied human brain tissues, his lab also works with HD mice to look at very early changes in the HD brain

11:29 – Reiner is working now to try to correlate patterns of change that he sees in HD mouse brains with their behavioral symptoms

11:34 – Reiner is interested in undersanding the origin of a movement symptom called “dystonia” in HD

11:37 – Dystonia, twisted and abnormal movements or postures, can be a debilitating symptom of HD, partricularly in later stages

11:37 – Reiner is studying the connection between patterns of cell loss in the HD brain and the presence of dystonia as a symptom

11:47 – George Rebec, Indiana University, measures the activity of brain cells in HD mice that are awake and behaving

11:49 – His mice wear “headsets” that record brain cell activity while the mice actively move around their cages

11:52 – Like Raymond, and others, Rebec is interested in communication between the “cortex” and “striatum”, and how this goes wrong in HD

11:58 – While observing HD mice, Rebec notices that they don’t like to sit still as much as normal mice, they seem restless

11:59 – Rebec can detect brain activity patterns that correlate with this restlessness, maybe explaining it’s cause

12:01 – He’s using a genetic trick in mice to get rid of the mutant HD gene in the cortex, but not the striatum, to figure out who’s in charge

12:07 – These mice seem a bit less restless, and a bit less “stubborn” in their behavior patterns

12:10 – Rebec’s take home message is “improper communication can be dangerous”, so fixing cortical problems might help other brain areas in HD

Sunset conclusions

This afternoon we took time to view and digest the 100 posters presented by the 300 scientists attending the meeting. These posters represent a huge amount of work from dozens of laboratories around the world. Most is unpublished, much is incredibly innovative and all is shared freely to foster collaboration and accelerate the development of treatments.

After that we heard from James Bradner of the Dana-Farber Cancer Institute. Bradner developed a drug molecule for a rare type of cancer then made the drug freely available to any researcher worldwide, leading to an explosion of therapeutic progress in many other diseases. We recalled Jonas Salk’s response to an interviewer asking whether he’d patent his life-saving polio vaccine: “Could you patent the sun?”

At HDBuzz, we are unashamed fans of sharing and the free flow of information. A spirit of openness runs through the HD scientific and patient community, fertilizing progress towards treatments.

Latest Research Articles

Getting to the Root of Huntington's Disease: A Plant-Based Approach

Published date: 15 October, 2023

Researchers studied a fragment of the Huntington’s disease (HD) protein in plants and found a new way to stop it from forming toxic clumps. A special plant protein that the team identified can prevent harmful buildup in plants as well as in some HD model systems, showing potential for this approach as a possible way ... Read more

Could halting CAG expansions be a new treatment for HD?

Published date: 5 October, 2023

A recent paper from a group at UMass Chan Medical School, spearheaded by Dr. Daniel O'Reilly and led by Dr. Anastasia Khvorova, used genetic strategies to lower a protein other than huntingtin. This time the researchers went after a gene called MSH3. This is a gene that’s been getting a lot of attention in Huntington’s ... Read more

Tipping the balance; new insights into HD genetic modifiers

Published date: 1 September, 2023

Genetic modifiers can influence when HD symptoms begin. Some of these genes encode for different types of molecular machines whose normal job is to repair our DNA when it is broken or damaged. A recently published study from scientists at Thomas Jefferson University uncovers details of how these molecular machines help repair damaged DNA structures ... Read more

Drug to treat movement symptoms of HD approved by FDA

Published date: 22 August, 2023

The vast majority of people with Huntington’s disease experience movement symptoms known as chorea. Valbenazine, also known as INGREZZA, has recently been approved by the United States Food and Drug Administration (FDA), allowing doctors in the USA to prescribe this medicine for Huntington’s disease (HD) chorea. In this article we go through the key points ... Read more

Youthful competitors: young brain cells oust the old

Published date: 8 August, 2023

When you lose something, an easy solution can be to just replace it. But what if the something you’ve lost are cells in the brain? Can they simply be replaced? Some researchers have been working toward this for Huntington’s disease (HD) by injecting new cells into the brains of animal models. A recent publication that ... Read more

Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials

Published date: 21 June, 2023

On 21st June, both PTC Therapeutics and uniQure shared data from their respective clinical trials, both testing huntingtin-lowering as an approach to treat HD, but with different types of therapies. In this article we go through the data they each presented, what it all means and the next steps the companies will be taking. Treating ... Read more